Loomis, Sayles & Company Portfolio holdings
AUM
$79.8B
1-Year Return
31.99%
This Quarter Return
+13.7%
1 Year Return
+31.99%
3 Year Return
+166.63%
5 Year Return
+219.21%
10 Year Return
+619.03%
AUM
$75.7B
AUM Growth
+$6.94B
(+10%)
Cap. Flow
-$374M
Cap. Flow
% of AUM
-0.49%
Top 10 Holdings %
Top 10 Hldgs %
38.84%
Holding
852
New
205
Increased
261
Reduced
298
Closed
58
Top Buys
| 1 |
Novartis
NVS
|
$908M |
| 2 |
Walt Disney
DIS
|
$621M |
| 3 |
Boeing
BA
|
$548M |
| 4 |
Starbucks
SBUX
|
$310M |
| 5 |
Schlumberger
SLB
|
$250M |
Top Sells
| 1 |
VAR
Varian Medical Systems, Inc.
VAR
|
$445M |
| 2 |
Ford
F
|
$212M |
| 3 |
Meta Platforms (Facebook)
META
|
$194M |
| 4 |
Visa
V
|
$192M |
| 5 |
Autodesk
ADSK
|
$189M |
Sector Composition
| 1 | Technology | 26.48% |
| 2 | Consumer Discretionary | 16.31% |
| 3 | Communication Services | 13.43% |
| 4 | Healthcare | 12.88% |
| 5 | Industrials | 11.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
426
Nuveen Floating Rate Income Fund
JFR
$1.13B
| $2.07M | ﹤0.01% |
236,650
| – | – |
|
427
iShares Core S&P 500 ETF
IVV
$664B
| $2.07M | ﹤0.01% |
5,500
| – | – |
|
|
NBIS
428
Nebius Group N.V. Class A Ordinary Shares
NBIS
$15.6B
| $2.02M | ﹤0.01% |
29,016
+11,622
| +67% | +$809K |
|
429
Credicorp
BAP
$20.7B
| $2M | ﹤0.01% |
12,191
+4,834
| +66% | +$793K |
|
430
Nike
NKE
$109B
| $2M | ﹤0.01% |
14,107
+10,758
| +321% | +$1.52M |
|
431
Core Laboratories
CLB
$592M
| $1.86M | ﹤0.01% |
70,004
+3,356
| +5% | +$89K |
|
432
Lam Research
LRCX
$130B
| $1.71M | ﹤0.01% |
36,240
+1,600
| +5% | +$75.5K |
|
|
ATVI
433
DELISTED
Activision Blizzard Inc.
ATVI
| $1.61M | ﹤0.01% |
17,320
+4,511
| +35% | +$419K |
|
434
Dollar General
DG
$24.1B
| $1.59M | ﹤0.01% |
7,561
+2,950
| +64% | +$620K |
|
435
Intuit
INTU
$188B
| $1.57M | ﹤0.01% |
4,133
+1,246
| +43% | +$473K |
|
436
HCA Healthcare
HCA
$98.5B
| $1.56M | ﹤0.01% |
9,502
+9,329
| +5,392% | +$1.53M |
|
437
United Airlines
UAL
$34.5B
| $1.55M | ﹤0.01% |
+35,904
| New | +$1.55M |
|
438
Thermo Fisher Scientific
TMO
$186B
| $1.55M | ﹤0.01% |
3,321
+2,732
| +464% | +$1.27M |
|
439
Eli Lilly
LLY
$652B
| $1.54M | ﹤0.01% |
9,125
+2,195
| +32% | +$371K |
|
440
Target
TGT
$42.3B
| $1.54M | ﹤0.01% |
8,731
+5,124
| +142% | +$904K |
|
441
Citigroup
C
$176B
| $1.53M | ﹤0.01% |
24,883
+3,889
| +19% | +$240K |
|
442
IBM
IBM
$232B
| $1.53M | ﹤0.01% |
12,720
-17
| -0.1% | -$2.05K |
|
443
Gen Digital
GEN
$18.2B
| $1.53M | ﹤0.01% |
73,362
+26,890
| +58% | +$559K |
|
444
Applied Materials
AMAT
$130B
| $1.52M | ﹤0.01% |
17,609
+999
| +6% | +$86.2K |
|
445
Humana
HUM
$37B
| $1.52M | ﹤0.01% |
3,702
+1,138
| +44% | +$467K |
|
446
Philip Morris
PM
$251B
| $1.51M | ﹤0.01% |
18,291
+4,662
| +34% | +$386K |
|
447
MetLife
MET
$52.9B
| $1.5M | ﹤0.01% |
31,836
+6,322
| +25% | +$297K |
|
448
Lowe's Companies
LOW
$151B
| $1.46M | ﹤0.01% |
9,110
+2,105
| +30% | +$338K |
|
449
Altria Group
MO
$112B
| $1.46M | ﹤0.01% |
35,487
+9,914
| +39% | +$406K |
|
450
Masco
MAS
$15.9B
| $1.44M | ﹤0.01% |
26,258
+9,468
| +56% | +$520K |
|